Document is current
Any future updates will be listed below
-
Authors
Zhu, James http://orcid.org/0000-0003-2713-1839
Wang, Yunguan
Chang, Woo Yong http://orcid.org/0000-0002-7129-5016
Malewska, Alicia
Napolitano, Fabiana http://orcid.org/0000-0002-2463-8952
Gahan, Jeffrey C.
Unni, Nisha
Zhao, Min
Yuan, Rongqing
Wu, Fangjiang
Yue, Lauren
Guo, Lei
Zhao, Zhuo
Chen, Danny Z. http://orcid.org/0000-0001-6565-2884
Hannan, Raquibul
Zhang, Siyuan http://orcid.org/0000-0003-0910-3666
Xiao, Guanghua http://orcid.org/0000-0001-9387-9883
Mu, Ping
Hanker, Ariella B. http://orcid.org/0000-0002-8655-8341
Strand, Douglas
Arteaga, Carlos L.
Desai, Neil
Wang, Xinlei http://orcid.org/0000-0002-8561-6511
Xie, Yang http://orcid.org/0000-0001-9456-1762
Wang, Tao http://orcid.org/0000-0002-4355-149X
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP190208, RP230363, RR220024, RR170061)
U.S. Department of Health & Human Services | National Institutes of Health (R01CA258584, R01CA255064, RC2DK129994, R01DK115477, R01DK135535)
Dedman Family Scholars in Clinical Care
- License Information
-
More Information
Article History
Received: 24 January 2024
Accepted: 2 August 2024
First Online: 3 September 2024
Competing interests
: T.W. receives personal consulting fees from Merck for projects unrelated to this study. A.B.H. receives or has received research grants from Takeda and Lilly and non-financial support from Puma Biotechnology and Tempus. C.L.A. receives or has received research grants from Pfizer, Lilly and Takeda; holds minor stock options in Provista; serves or has served in an advisory role to Novartis, Merck, Lilly, Daiichi Sankyo, Taiho Oncology, OrigiMed, Puma Biotechnology, Immunomedics, AstraZeneca, Arvinas and Sanofi; and reports scientific advisory board remuneration from the Susan G. Komen Foundation. The other authors declare no competing interests.
